Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2023-12-08 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks for Ascletis Pharma Inc. It details numerous repurchases of shares over a period, with dates and quantities, and includes confirmations related to the authorization and compliance of these share repurchases. The document references the Main Board Listing Rules and GEM Listing Rules of the Stock Exchange of Hong Kong, indicating it is a regulatory disclosure related to share capital changes. It does not contain financial statements or earnings data, nor is it a report or presentation. It is a detailed report of the company's transactions in its own shares (share buybacks). Therefore, the document fits the category of 'Transaction in Own Shares' (POS). The document length and detail support a high confidence in this classification.
2023-12-08 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed data on repurchases of shares over multiple dates, confirming compliance with listing rules of the Stock Exchange of Hong Kong (SEHK). The content is a regulatory disclosure about share repurchases, not a financial report or earnings release. It is a formal notification of share capital changes and repurchase transactions. This fits the category of 'Transaction in Own Shares' (POS), which covers reports of the company buying back or selling its own shares. The document length and detail confirm it is the report itself, not just an announcement of a report.
2023-12-07 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchase transactions with dates and quantities, referencing specific listing rules of the Stock Exchange of Hong Kong (SEHK). The content is focused on reporting share repurchases and changes in share capital, which aligns with announcements regarding share repurchase activities. There is no indication of financial statements, earnings data, or management discussion. The document is not a full financial report but a regulatory disclosure of share repurchase transactions. Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length (15,000 characters) supports it being a detailed report rather than a brief announcement, reinforcing the POS classification.
2023-12-06 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed data on repurchases of shares over multiple dates, confirming compliance with listing rules of the Stock Exchange of Hong Kong (SEHK). The content is a regulatory disclosure of share repurchase activity, not a financial report or earnings release. It is a formal notification of transactions in own shares, specifically share buybacks, with no financial statements or management commentary. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length and detail confirm it is not a brief announcement but a full disclosure return.
2023-12-05 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES INITIATION OF PHASE III CLINICAL TRIAL OF ASC40 (DENIFANSTAT) FOR TREATMENT OF ACNE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the initiation of a Phase III clinical trial for a drug candidate ASC40. It provides details about the clinical trial design, endpoints, regulatory approvals, and background information on the drug and disease. There is no financial data, no mention of financial results, no regulatory filings about financial performance, no voting results, no management changes, no capital or financing updates, and no other report types. The document is an announcement of a business development event (clinical trial initiation) rather than a financial or regulatory report. It is not a report publication announcement since it does not mention any report being published or attached. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2023-12-05 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2023
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' for the month ended 30 November 2023. It details movements in authorized and issued shares, share options, repurchases, and confirmations related to share capital. The document is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting share capital movements and share repurchases. It does not contain financial statements, earnings data, management discussion, or audit information. It is a regulatory compliance filing specific to share capital movements and repurchases, which fits the category of Share Issue/Capital Change announcements. The document length is 7282 characters, which is substantive and contains detailed data on share capital changes, not merely an announcement of a report. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2023-12-05 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.